TL;DR
- •The FDA conducted a comprehensive review of GLP-1 medications and mood, published January 13, 2026, analyzing 91 clinical trials and 107,910 participants. The conclusion: no causal link between GLP-1 medications and suicidal ideation or suicide at the population level.
- •As a result of that review, the FDA REMOVED the suicidal ideation warning from Saxenda, Wegovy, and Zepbound — the weight-loss GLP-1s. Note: Ozempic, Mounjaro, Victoza, Rybelsus, and the diabetes GLP-1s never carried the warning in the first place.
- •But individual patient reports of mood changes on GLP-1s are real. Some patients experience sadness, anxiety, anhedonia, or worsening of pre-existing depression. The population-level analysis doesn't invalidate individual experience — it just means GLP-1s aren't systematically causing mood problems.
- •Plausible mechanisms for individual reports: rapid weight loss reduces leptin and other appetite-mood signaling; reduced food enjoyment (anhedonia for food) generalizes to broader anhedonia in vulnerable patients; metabolic shifts affect sleep and energy.
- •Distinguishing the contributors matters: pre-existing depression, rapid weight changes, life stressors, and other medications all interact. A mood change while starting a GLP-1 isn't automatically caused by the GLP-1 — but the patient experience deserves careful assessment.
- •For patients on GLP-1s for weight or metabolic indication who experience mood changes, options range from screening and treating depression with established treatments, to discussing GLP-1 continuation vs alternatives, to mechanism-specific depression treatments like ketamine for treatment-resistant cases.
- •Today's blog post at /blog/does-ozempic-cause-depression-glp-1-mood covers the FDA review in detail.
Medications most associated with this
What this is
GLP-1 mood changes are the cluster of mood-related symptoms some patients report after starting GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, etc.). Reports include: sadness or low mood not clearly tied to life circumstances, anxiety that wasn't present before, anhedonia (loss of pleasure in activities — sometimes starting with food, sometimes generalizing), social withdrawal, irritability, and in a smaller subset, suicidal ideation. These reports prompted FDA investigations and patient advocacy concerns, which culminated in the January 2026 review. The population-level finding: no causal link. The individual-level reports: real and worth careful assessment. See also /blog/does-ozempic-cause-depression-glp-1-mood for the full picture.
Why it happens
The FDA's January 13, 2026 review of 91 trials and 107,910 participants found no causal link at the population level between GLP-1 medications and suicidal ideation or completed suicide — and the suicidal ideation warning was removed from Saxenda, Wegovy, and Zepbound. A 2026 pharmacovigilance analysis and a 2026 Biological Psychiatry review reach similar conclusions about the absence of a class effect. Some emerging research even suggests possible mood-protective effects via central GLP-1 receptor pathways. But case reports continue, and patient-level mechanisms remain plausible: rapid weight loss affects leptin and other mood-relevant hormones; reduced food enjoyment can generalize to broader anhedonia in vulnerable patients; metabolic shifts can affect sleep and energy. The right frame: GLP-1s don't broadly cause depression, but in individual patients, multiple factors during treatment (including the medication, the weight changes, life stressors, and pre-existing risk) can interact to produce mood changes worth taking seriously.
Typical timeline
When mood changes are reported, onset is variable — some patients report changes in the first few weeks of starting the GLP-1 or after dose escalations; others not until months in. Many reports cluster around the period of fastest weight loss (months 3-9). After discontinuation, mood changes typically resolve over weeks-to-months, though distinguishing GLP-1-related from other contributors (untreated depression, life stressors) requires careful clinical assessment.
Management options
Discuss with your prescriber before adjusting any medication. These are options to bring up in conversation.
Screen for depression with standardized tools
PHQ-9 and GAD-7 provide objective measurement. If scores are elevated, the depression deserves treatment regardless of cause. Reassess every 2-4 weeks during dose changes and during the weight-loss period.
Distinguish contributors before changing the GLP-1
Pre-existing depression, rapid weight changes, life stressors, sleep disruption, and other medications all contribute. A careful assessment with your prescriber and a mental health clinician (if available) helps identify what's driving what. Don't automatically discontinue the GLP-1 if mood symptoms appear — the population evidence doesn't support that as the right default.
Treat depression with established treatments first
If depression is diagnosed, standard treatments apply: psychotherapy (CBT, interpersonal therapy), SSRI/SNRI antidepressants, behavioral activation, exercise, sleep optimization. The GLP-1 typically can continue while depression treatment proceeds.
Consider GLP-1 dose reduction
For patients whose mood symptoms began with GLP-1 escalation, a dose reduction sometimes resolves the symptoms while maintaining metabolic benefit. Discuss with your prescriber.
Discuss GLP-1 continuation vs alternative
If mood symptoms are severe and not responding to standard depression treatment, and if the timing strongly suggests a GLP-1 contribution, discussing GLP-1 alternatives or discontinuation may be appropriate. This is a clinical decision balancing metabolic benefit against mood impact for the individual patient.
Mechanism switch to ketamine for treatment-resistant cases
For patients with treatment-resistant depression where the relationship to the GLP-1 is unclear and standard antidepressants haven't produced response, ketamine's NMDA/glutamate mechanism doesn't interact with GLP-1 pathways and provides rapid antidepressant effect. The combination is well-tolerated when clinically appropriate.
Where ketamine fits
For most patients reporting mood changes on GLP-1 medications, the right first-line approach is standard depression screening and treatment — not jumping to ketamine. The FDA's 2026 review didn't find a class effect, and individual mood changes are often best treated with established depression interventions while continuing the GLP-1 for its metabolic benefit. Ketamine's role is in the treatment-resistant subset: patients whose depression is severe and not responding to standard antidepressants, where the question is no longer "is the GLP-1 causing this?" but "what depression treatment will work?" Ketamine's NMDA/glutamate mechanism doesn't overlap with GLP-1 pathways and is well-tolerated in patients continuing GLP-1 therapy.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Does Ozempic cause depression?
Not at the population level. The FDA's January 2026 review of 91 trials and 107,910 participants found no causal link between GLP-1 medications (including Ozempic) and suicidal ideation or suicide. The suicidal ideation warning was removed from Saxenda, Wegovy, and Zepbound as a result — Ozempic, Mounjaro, Victoza, and Rybelsus never carried that warning. That said, individual reports of mood changes on GLP-1s are real, and your individual experience deserves careful assessment. See /blog/does-ozempic-cause-depression-glp-1-mood for the full FDA review breakdown.
I really feel different on Wegovy. Is it the medication?
It might be — but it might also be the rapid weight loss, life stressors during the treatment period, pre-existing depression that was masked, sleep changes from the metabolic shift, or interaction with other medications. A careful assessment with your prescriber and (ideally) a mental health clinician can sort through the contributors. Don't dismiss your experience because the population-level data is reassuring; equally, don't assume the medication is the only factor.
Should I stop my GLP-1 if I'm feeling depressed?
Not automatically. The right first step is depression screening (PHQ-9), assessment of contributors, and treatment of the depression with established interventions (therapy, antidepressants, lifestyle). For most patients, the GLP-1 can continue while depression treatment proceeds. If severe depression is clearly time-locked to GLP-1 dose changes and not responding to depression treatment, discussing discontinuation makes sense. This is an individualized clinical decision.
Why was the suicidal ideation warning removed from Wegovy but not Ozempic?
Ozempic never carried the suicidal ideation warning in the first place. The warning was on Saxenda (liraglutide for weight), Wegovy (semaglutide for weight), and Zepbound (tirzepatide for weight) — the weight-loss GLP-1s, where regulators were watching closely because of the weight-loss medication class history of psychiatric concerns. After the FDA's 2026 review found no class effect, the warning was removed from those three medications. The diabetes GLP-1s (Ozempic, Mounjaro, Victoza, Trulicity, Rybelsus, Byetta) never had the warning.
Could ketamine help if my mood changes don't respond to standard treatment?
Potentially, yes — for treatment-resistant cases. Ketamine's NMDA/glutamate mechanism doesn't interact with GLP-1 pathways and provides rapid antidepressant effect when standard antidepressants haven't worked. The decision to consider ketamine is the same as it would be in any treatment-resistant depression: typically after 2+ adequate trials of standard antidepressants without sufficient response. Most patients on GLP-1s with mood changes won't need to escalate to ketamine — but for the treatment-resistant subset, the mechanism makes sense alongside continued GLP-1 therapy.
Don’t stop your medication on your own
Even mild side effects deserve a clinical conversation. Stopping or adjusting antidepressants without coordination with your prescriber can cause discontinuation syndrome, depression breakthrough, or both. Bring these options to your next appointment.
References
- Anderer S. 2026, JAMA. FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications — January 13, 2026 review of 91 trials and 107,910 participants finding no causal link. PMID 41615669
- SeijasAmigo J et al. 2026, Int J Clin Pharm. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 RAs — confirms absence of class-level signal in pharmacovigilance data. PMID 41739406
- McIntyre RS. 2026, Biol Psychiatry. Implications of GLP-1 Receptor Agonists for Mood Disorders — review of mechanistic and clinical evidence including possible mood-protective effects. PMID 42069105
- Manoharan SVRR et al. 2024, Innov Clin Neurosci. GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide) — case report supporting individual-level reports despite population-level findings. PMID 38938530
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — relevant for treatment-resistant cases regardless of suspected GLP-1 contribution. PMID 28249076